financetom
Business
financetom
/
Business
/
National Bank Previews Dollarama's Q1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Bank Previews Dollarama's Q1
May 26, 2025 12:46 PM

01:16 PM EDT, 05/22/2025 (MT Newswires) -- Dollarama ( DLMAF ) will report its first-quarter results on June 11.

National Bank is forecasting earnings per share of $0.84, in line with consensus; last year was $0.77. "Our expectation of 8% y/y EPS growth primarily reflects positive sssg, LTM net new store openings (72; square footage growth of 4.6% y/y), Dollarcity contribution, share repurchases over the last 12 months, and operating leverage," said analyst Vishal Shreedhar.

Maintain Outperform rating; price target raised to $182 from $176.

Price: 172.55, Change: +0.71, Percent Change: +0.41

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Dr. Reddy's, Alvotech Say FDA Accepts Biologic License Application for Bone Drug Biosimilar
Dr. Reddy's, Alvotech Say FDA Accepts Biologic License Application for Bone Drug Biosimilar
Mar 18, 2025
09:04 AM EDT, 03/18/2025 (MT Newswires) -- Dr. Reddy's Laboratories (RDY) and Alvotech ( ALVO ) said Tuesday that the US Food and Drug Administration has accepted a biologic license application submission for AVT03, a proposed biosimilar of bone disease treatments Prolia and Xgeva. Dr. Reddy's and Alvotech ( ALVO ) last year entered into a license and supply agreement...
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain
Dogwood Therapeutics Begins Dosing in Mid-Stage Study of Halneuron for Chemotherapy-Related Neuropathic Pain
Mar 18, 2025
09:03 AM EDT, 03/18/2025 (MT Newswires) -- Dogwood Therapeutics ( DWTX ) said Tuesday it has begun dosing patients in a phase 2b trial testing Halneuron for chemotherapy-induced neuropathic pain. The company said it plans to enroll 100 patients by Q4 when it expects to conduct an interim analysis to assess trial progress and make any necessary adjustments. Shares of...
Jaguar Health to Implement 1-for-25 Reverse Stock Split
Jaguar Health to Implement 1-for-25 Reverse Stock Split
Mar 18, 2025
09:03 AM EDT, 03/18/2025 (MT Newswires) -- Jaguar Health ( JAGX ) said Tuesday that it will implement a 1-for-25 reverse stock split of its issued and outstanding voting common stock to ensure compliance with Nasdaq listing standards. The company said the stock will begin trading on a split-adjusted basis when the market opens on Monday and will remain listed...
Putin tells Russian business not to count on fully free trade even if Western sanctions are eased
Putin tells Russian business not to count on fully free trade even if Western sanctions are eased
Mar 18, 2025
MOSCOW (Reuters) - President Vladimir Putin told Russian business leaders on Tuesday not to count on fully free trade or movement of capital being restored in the event of Western sanctions on Russia being eased. Our competitors will always want to weaken and contain us, Putin told a meeting with Russian businessmen. Even if one side will make a gesture...
Copyright 2023-2026 - www.financetom.com All Rights Reserved